Medigene Takes Center Stage In Roivant's Latest 'Vant'

 
• By Kevin Grogan

Roivant has launched its 16th Vant, called Cytovant, which hopes to be Asia's premier cell therapy company. It has inked a deal worth potentially $1bn with Germany's Medigene to develop TCR immunotherapies and a dendritic cell vaccine.

Germany - China
Medigene of Germany's cell therapies to be developed for China through Cytovant deal • Source: Shutterstock

More from China

More from Focus On Asia